N-ACETYLCYSTEINE OR ASCORBIC ACID VERSUS PLACEBO TO PREVENT CONTRAST-INDUCED NEPHROPATHY IN PATIENTS WITH RENAL INSUFFICIENCY UNDERGOING ELECTIVE CARDIAC CATHETERIZATION: A SINGLE CENTER, PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL  by Brueck, Martin et al.
E595
JACC April 5, 2011
Volume 57, Issue 14
   GENERAL CARDIOLOGY: HYPERTENSION, PREVENTION AND LIPIDS
N-ACETYLCYSTEINE OR ASCORBIC ACID VERSUS PLACEBO TO PREVENT CONTRAST-INDUCED 
NEPHROPATHY IN PATIENTS WITH RENAL INSUFFICIENCY UNDERGOING ELECTIVE CARDIAC 
CATHETERIZATION: A SINGLE CENTER, PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED, 
RANDOMIZED TRIAL
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Monday, April 04, 2011, 3:30 p.m.-4:45 p.m.
Session Title: Risk Reduction and Rehabilitation: Medical Therapy
Abstract Category: 17. Risk Reduction and Rehabilitation
Session-Poster Board Number: 1115-293
Authors: Martin Brueck, Huelya Cengiz, Andreas Boening, Department of Internal Medicine, Clinic of Wetzlar, Wetzlar, Germany, Department of 
Cardiovascular Surgery, University of Giessen, Giessen, Germany
Background. Contrast-induced nephropathy (CIN) is a recognized complication after contrast agent administration especially in patients with 
renal dysfunction that has been associated with longer hospitalization and adverse clinical outcome. The objective of the study was to investigate 
whether the use of 2 antioxidants, N-acetylcysteine (NAC) or ascorbic acid, reduce the incidence of CIN in adequately prehydrated patients with 
chronic renal insufficiency.
Methods. In this randomized, double-blind, prospective, placebo-controlled, single-center study, 520 consecutive patients with stable renal 
insufficiency (creatinine clearance < 60 mL/min) undergoing elective coronary angiography with or without intervention were randomly assigned 
using a computer-generated list of 3 blocks on a 2:2:1 basis to NAC, ascorbic acid or placebo on the day before and the day of angiography. 
Only iopromide, a nonionic, low-osmolality contrast agent, was used. Primary endpoint was the incidence of CIN defined as an increase in serum 
creatinine concentration of > 0.5 mg/dL (> 44 μmol/L) within 72 hours after contrast agent exposure.
Results. A total of 520 patients were enrolled and constituted the safety population, while 483 patients completed the study per protocol. 
Demographic characteristics, contrast volume and incidence of diabetes mellitus (51.7 %) were comparable in the 3 groups. The primary endpoint 
of CIN occurred in 27.6 % (53 of 192 patients) receiving NAC, 24.5 % (24 of 98 patients) receiving ascorbic acid and 32.1 % (62 of 193 patients) 
receiving placebo. The rate of CIN was not different between the 3 groups (placebo vs NAC p = 0.37, placebo vs ascorbic acid p = 0.22, NAC vs 
ascorbic acid p = 0.67). The failure of a preventive effect of NAC and ascorbic acid was consistent among various patient subgroups.
Conclusion. There remains a high incidence of CIN despite prehydration in patients with preexisting renal dysfunction undergoing coronary 
angiography and/or intervention. The prophylactic administration of the antioxidants NAC or ascorbic acid, along with prehydration, was not 
associated with a significantly reduced risk of CIN compared with placebo in patients with chronic renal insufficiency.
